Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept

被引：3
作者：
Arita, Yuki [1 ]
Taguchi, Hiroaki [2 ]
Kobayashi, Mari [1 ]
Tono, Toshihiro [2 ]
Ohsone, Yasuo [2 ]
Okano, Yutaka [2 ]
机构：
[1] Kawasaki Municipal Kawasaki Hosp, Dept Internal Med, Kawasaki, Kanagawa, Japan
[2] Kawasaki Municipal Kawasaki Hosp, Ctr Arthrit & Rheumat Dis, Kawasaki, Kanagawa, Japan
来源：
MODERN RHEUMATOLOGY | 2018年 / 28卷 / 06期
关键词：
Disease-modifying antirheumatic drug; Iguratimod; Pneumocystis jirovecii pneumonia; Rheumatoid arthritis; ANTIRHEUMATIC DRUG; DOUBLE-BLIND; THERAPY; EFFICACY;
D O I：
10.1080/14397595.2016.1181026
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 66-year-old woman who had rheumatoid arthritis and underwent a long-term treatment with methotrexate and etanercept developed Pneumocystis jirovecii pneumonia (PCP) 3 months after iguratimod add-on. Although most rheumatologists might have the impression that iguratimod has less toxicity and immunosuppressive effect compared with methotrexate and biologic disease-modifying antirheumatic drugs, this case suggests that iguratimod may increase the risk of PCP, especially in combination with other drugs.
引用
收藏
页码：1041 / 1043
页数：3
相关论文
共 31 条
  • [21] Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial
    Worawit Louthrenoo
    Surasak Nilganuwong
    Ratanavadee Nanagara
    Boonjing Siripaitoon
    Sabine Collaud Basset
    Clinical Rheumatology, 2019, 38 : 2461 - 2471
  • [22] Pneumocystis jirovecii pneumonia complicating methotrexate treatment in a patient with low-risk post-molar gestational trophoblastic neoplasia: A case report and review of the literature
    Porragas-Paseiro, Hector S.
    Johnson, Steven
    Brubaker, Lindsay
    Sanders, Brooke E.
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 50
  • [23] Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor inhibitor due to clinical remission
    Naniwa, Taio
    Iwagaitsu, Shiho
    Kajiura, Mikiko
    MODERN RHEUMATOLOGY, 2017, 27 (01) : 29 - 34
  • [24] Successful treatment of severe Pneumocystis Jirovecii pneumonia in a diffuse large B-cell lymphoma patient after R-CHOP chemotherapy: A case report
    Xu, Yan
    Li, Zhaolin
    Ouyang, Lamei
    Su, Yinqing
    Wang, Canmin
    SAGE OPEN MEDICAL CASE REPORTS, 2023, 11
  • [25] Septic Shock after Seasonal Influenza Vaccination in an HIV-Infected Patient during Treatment with Etanercept for Rheumatoid Arthritis: a Case Report
    De Nardo, Pasquale
    Bellagamba, Rita
    Corpolongo, Angela
    Gentilotti, Elisa
    Taglietti, Fabrizio
    Rosati, Silvia
    Galeazzi, Mauro
    Sebastiani, Gian Domenico
    Quinti, Isabella
    Nicastri, Emanuele
    CLINICAL AND VACCINE IMMUNOLOGY, 2013, 20 (05) : 761 - 764
  • [26] Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial
    Verschueren, P.
    De Cock, D.
    Corluy, L.
    Joos, R.
    Langenaken, C.
    Taelman, V.
    Raeman, F.
    Ravelingien, I.
    Vandevyvere, K.
    Lenaerts, J.
    Geens, E.
    Geusens, P.
    Vanhoof, J.
    Durnez, A.
    Remans, J.
    Vander Cruyssen, B.
    Van Essche, E.
    Sileghem, A.
    De Brabanter, G.
    Joly, J.
    Meyfroidt, S.
    Van der Elst, K.
    Westhovens, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (01) : 27 - 34
  • [27] Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: A case report
    Kuroda T.
    Sato H.
    Nakatsue T.
    Wada Y.
    Murakami S.
    Nakano M.
    Narita I.
    BMC Research Notes, 7 (1)
  • [28] Guillain-Barrè syndrome after treatment with anti-tumour necrosis factor α (etanercept) in a rheumatoid arthritis patient: Case report and literature review
    Doden, Mera H.
    Manasra, Mahmoud R.
    Abuirayyeh, Bara M.
    Al-Ihribat, Alaa R.
    Albandak, Maram
    SCIENCE PROGRESS, 2024, 107 (04)
  • [29] Successful resolution of pneumonia developed in a patient affected by Crohn’s disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor α inhibitors and conventional immunosuppressive drugs
    Erika Angelucci
    Monica Cesarini
    Piero Vernia
    Rheumatology International, 2010, 30 : 977 - 978
  • [30] Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor α inhibitors and conventional immunosuppressive drugs
    Angelucci, Erika
    Cesarini, Monica
    Vernia, Piero
    RHEUMATOLOGY INTERNATIONAL, 2010, 30 (07) : 977 - 978
1234